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Background and purpose — Bisphosphonates are widely used 
in the treatment of bone loss, but they might also have positive 
effects on osteoblastic cells and bone formation. We evaluated 
the effect of in vivo zoledronic acid (ZA) treatment and possible 
concomitant effects of ZA and fracture on the ex vivo osteogenic 
capacity of rat mesenchymal stromal cells (MSCs). 
Methods — A closed femoral fracture model was used in adult 
female rats and ZA was administered as a single bolus or as 
weekly doses up to 8 weeks. Bone marrow MSCs were isolated 
and cultured for in vitro analyses. Fracture healing was evalu-
ated by radiography, micro-computed tomography (µCT), and 
histology.
Results — Both bolus and weekly ZA increased fracture-site 
bone mineral content and volume. MSCs from weekly ZA-treated 
animals showed increased ex vivo proliferative capacity, while no 
substantial effect on osteoblastic differentiation was observed. 
Fracture itself did not have any substantial effect on cell prolif-
eration or differentiation at 8 weeks. Serum biochemical markers 
showed higher levels of bone formation in animals with fracture 
than in intact animals, while no difference in bone resorption 
was observed. Interestingly, ex vivo osteoblastic differentiation of 
MSCs was found to correlate with in vivo serum bone markers.
Interpretation — Our data show that in vivo zoledronic acid 
treatment can infl uence ex vivo proliferation of MSCs, indicating 
that bisphosphonates can have sustainable effects on cells of the 
osteoblastic lineage. Further research is needed to investigate the 
mechanisms.
■
Bisphosphonates (BPs) are potent inhibitors of bone resorption 
and osteoclasts are the primary target (Fleisch 2000, Rogers 
2003). Several studies have nevertheless found an osteogenic 
response when mature osteoblasts are continuously treated 
with BPs in vitro (Reinholz et al. 2000, Fromigué and Body 
2002, Im et al. 2004, Pan et al. 2004). Giuliani et al. (1998) 
injected young female mice with alendronate and etidronate 
and then isolated and cultured bone marrow (BM) cells ex 
vivo. Interestingly, they found mild but positive effects on the 
formation of alkaline phosphatase- (ALP-) positive colonies, 
indicating a proliferative and/or osteogenic effect in vivo. Li et 
al. (1999, 2000) found that continuous incadronate treatment 
led to larger callus formation and delayed callus remodeling 
in an endochondral rat femoral fracture model. Using the same 
experimental model, McDonald et al. (2008) showed that 
zoledronic acid (ZA) treatment led to increased hard callus 
bone mineral content (BMC), increased bone volume (BV), 
and increased callus strength. 
Our previous study evaluating the effect of adjunct ZA treat-
ment on bioactive incorporation in a rat medullary ablation 
model showed that continuous ZA treatment alone resulted in 
an intense trabecular bone accumulation during the 9-week 
follow-up period (Välimäki et al. 2006). Our preliminary 
analyses on BM mesenchymal stromal cells (MSCs) har-
vested from the ZA-treated rats indicated that ZA—in doses 
that were comparable to a clinical dose—could enhance the 
osteogenesis of MSCs (unpublished data). The current study 
was carried out to investigate possible effects of ZA on MSCs 
by determining whether ZA treatment in vivo affects prolif-
eration and differentiation of MSCs ex vivo. We hypothesized 
that ZA would enhance proliferation and osteoblastic differen-
tiation of MSCs, and we also investigated whether this effect 
would be more evident in the presence of fracture.
Methods
Animals, randomization, and experimental groups
The study protocol was approved by the National Animal 
Experiment Board (#ESHL-2009-08666/Ym23). 50 female 
Harlan Sprague-Dawley rats (mean age 19 (16–23) weeks and 
weight 286 (224–351) g) were obtained for the study, which 
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was planned and executed according to the 3Rs of humane 
animal research. 31 animals were initially operated, but 2 were 
excluded because of non-mid-diaphyseal or comminuted frac-
ture, and 2 because of failed fracture fi xation during follow-
up. 19 animals remained intact. Primary MSC cultures from 6 
animals were lost due to contamination. Thus, altogether 40 
animals completed the study. 
Animals were fi rst randomized to the fracture group or the 
intact group. 1 week after fracture surgery, they were random-
ized to weekly ZA, bolus ZA, or placebo. The 6 experimental 
groups were: intact with weekly placebo (I-P, n = 6); intact with 
bolus ZA (I-Z-B, n = 6); intact with weekly ZA (I-Z-W, n = 6); 
fracture with weekly placebo (F-P, n = 8); fracture with bolus 
ZA (F-Z-B, n = 7); and fracture with weekly ZA (F-Z-W, n = 7)
Fracture surgery and digital radiography
The animals were anesthetized with intramuscular adminis-
tration of ketamine hydrochloride and medetomidine. Using 
standard sterile surgical techniques, a small incision was made 
anterior to the patella of the right distal femur. The patella was 
moved laterally to reveal the distal femoral condyles, and a 
1.0-mm Kirschner wire was inserted into the medullary canal. 
A transverse mid-diaphyseal closed femoral fracture was 
induced using a drop-weight fracture apparatus (Hiltunen et 
al. 1993), which was designed according to Bonnarens and 
Einhorn (1984). For postoperative pain relief, buprenorphine 
(0.01 mg/kg) was administered subcutaneously twice a day 
for 3 days. The location and quality of each fracture was 
evaluated using the Faxitron digital radiography system (MX-
20; Faxitron X-ray Corporation, Wheeling, IL) and Faxitron 
Imaging Software (Qados; Cross Technologies plc, Berkshire, 
UK). All the animals underwent imaging at 0, 4, and 8 weeks. 
They were maintained on regular chow and water in 1,029 
cm2 cages (2–3 animals/cage, 21°C ± 2°C, 55 ± 15 relative 
humidity) with a 12-h light/dark cycle throughout the study. 
Animal welfare was monitored on a daily basis.
Zoledronic acid and placebo administration
Starting 1 week after fracture, ZA (Novartis Pharma) was 
administered subcutaneously as a single bolus of 0.1 mg/kg or 
as 7 weekly doses of 0.014 mg/kg, resulting in the same total 
dose of 0.1 mg/kg. This was comparable to the annual dose of 
5 mg used clinically in treatment of patients with osteoporosis. 
Animals on placebo treatment received weekly subcutaneous 
injections of saline at 2 mL/kg.
Sample preparation and histology
8 weeks after fracture, all the animals were anesthetized. 
Blood samples were drawn by cardiac puncture and serum 
was collected. After that, the animals were killed using CO2. 
Both femurs and tibias were harvested. The left femur and 
left tibia were quickly cleaned in 70% ethanol and immedi-
ately transferred to cell culture facilities. Right femurs (intact 
or fractured) were radiographed, fi xed in 10% formalin, and 
stored in 70% ethanol until micro-computed tomography 
(µCT) analysis was completed. After µCT, right femurs were 
decalcifi ed (in 14% EDTA), followed by dehydration and 
embedding in paraffi n. 5-µm tissue sections were stained with 
Weigert’s hematoxylin, Alcian blue, and van Gieson.
Micro-computed tomography
Fractured and intact femurs were scanned with µCT (Sky-
Scan 1072). Specimens were rotated 180°, obtaining an image 
every 0.45° at 14.65-µm resolution. 3D analysis from a stan-
dardized 15-mm mid-diaphyseal segment comprising the 
fracture was performed with CTAn software (SkyScan) using 
calibration with 2 phantoms (250 and 750 mg/cm3) provided 
by the manufacturer (Salmon 2005). Bone mineral density 
(BMD), bone mineral content (BMC), and bone volume (BV) 
of healing and intact bone were measured by fi tting Gaussian 
curves to grayscale histograms using Origin software (Origin 
Lab Corp., Northampton, MA). This method was also used to 
calculate global threshold values, to segment data sets for 3D 
reconstructions.
Bone marrow cell isolation and MSC cultures
In a laminar-fl ow cabinet, epiphyses were cut and bone marrow 
(BM) fl ushed out using basal medium (α-MEM containing 
10% fetal bovine serum and antibiotics). Bones from each 
animal were processed separately. Cells were centrifuged, 
passed through a 22-G needle, plated at 106 cells/cm2, and 
cultured in basal medium. After 48 h, non-adherent cells were 
removed by rinsing twice with PBS and fresh basal medium 
containing 10-8 M dexamethasone (from here on referred to as 
MSC medium) was added. Half of the medium was changed 
on day 6. After 8–9 days, plastic adherent MSCs (passage 0) 
were trypsinized and counted before re-plating.
Osteoblast differentiation cultures and analysis
For osteogenesis, passage-0 cells were plated at 5,000 cells/
cm2 in 24-well plates and cultured either in MSC medium or 
in osteoblast induction medium (MSC medium with 10 mM 
β-glycerophosphate and 70 µg/mL ascorbic acid; from here on 
referred to as OB medium). Half of the medium was replaced 
every 3–4 days. Osteoblastic differentiation was evaluated 
after 2 weeks of induction culturing by staining for ALP and 
von Kossa and by measuring alkaline phosphatase (ALP) 
activity (Heino et al. 2004). For each read-out method, osteo-
genic induction was performed in 4 replicate wells per sample 
and 2 wells per sample served as control (MSC medium). 
Stained areas were quantifi ed using automated image analysis 
(Alm et al. 2012). 
Analysis of proliferative capacity and population 
doubling 
Passage-0 MSCs were expanded at 5,000 cells/cm2 in basal 
medium up to passage 7 (at 9–10 weeks). Half of the medium 
was replaced every 3–4 days, and the cells were monitored and 
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trypsinized when subconfl uent for further passaging. Popula-
tion doublings (PDs) at each passage were determined using 
the formula log(N)/log(2), where N is the number of cells at 
harvest divided by the number of cells plated. The cumulative 
PDs through passages 0–7, the maximum PDs and total PDs 
reached throughout passage 7, and the population doubling 
time (PDT) in days were analyzed.
Biochemical markers of bone metabolism
C-terminal crosslinked telopeptides of type-I collagen (CTX) 
as a resorption marker and N-terminal propeptides of type-I 
collagen (PINP) as a formation marker were measured in the 
serum samples obtained at killing, using RatLaps EIA and 
Rat/Mouse PINP EIA, respectively (both from IDS Nordic 
A/S, Copenhagen, Denmark).
Statistics 
To examine the effects of ZA, independently of fracture, pair-
wise comparisons between the intact groups and the fractured 
groups were performed separately using 1-way analysis of vari-
ance (ANOVA) with Tukey’s post hoc test. The effects of frac-
ture on the different parameters were examined by comparing 
each fracture group with its corresponding intact group using 
Student’s t-test. In cases where data were not normally distrib-
uted or had unequal variances, analyses were performed with 
the Kruskal-Wallis test followed by pairwise Mann-Whitney 
U-test. For evaluation of osteogenic differentiation of MSCs 
from different treatment groups, mixed-models ANOVA was 
used, with treatment group as fi xed factor and rat identifi cation 
number as random factor, to allow for multiple replicates from 
each individual rat. In the mixed-models analysis, restricted 
maximum likelihood (REML) was used as the method for esti-
mations, and pairwise comparisons of the estimated marginal 
means was performed using the Sidak’s test option. The intact 
groups and the fracture groups were analyzed separately, with 
pairwise comparisons performed between the 3 subgroups (P, 
Z-B, and Z-W). These data are presented as estimated marginal 
means with 95% confi dence intervals (CIs). Mixed-models 
analysis was chosen to increase statistical power, due to large 
variability within the groups. Linear correlation analysis was 
used to explore possible associations between ex vivo MSC 
parameters with µCT-measured fracture healing parameters 
and serum markers. For correlation analysis, all data were 
checked for outliers. Statistical analyses were performed using 
IBM SPSS Statistics version 22.
Results
Both bolus and weekly ZA increased the bone min-
eral content and bone volume at the fracture site
The health status of all animals was normal prior to frac-
ture surgery and no adverse effects were observed during 
the follow-up. Radiography showed radiological union by 8 
weeks regardless of treatment (Figure 1). Callus formation 
appeared more extensive in ZA-treated rats, and µCT images 
and histological sections supported this fi nding. No apparent 
differences were detected between the bolus and weekly ZA 
treatment groups. As expected, µCT analysis showed statisti-
cally signifi cantly greater BMC and BV in the callus areas 
of  fractured femurs than in intact femurs, while the callus 
areas had similar BMD (Figures 1 and 2). In intact animals, 
no statistically signifi cant differences were found between the 
placebo group, the weekly ZA treatment group, and the bolus 
ZA treatment group. When we compared ZA treatment and 
placebo treatment in animals with fracture, ZA treatment had 
the effect of increasing both femoral BMC and BV in callus 
areas. The weekly treatment group showed the highest average 
values of BMC and BV, but the difference was not statistically 
signifi cant (Figure 2). 
Weekly ZA treatment in vivo stimulated the ex vivo 
proliferation of MSCs isolated from intact animals, 
while ZA had no effect on osteoblastic differentiation
Similar numbers of BM cells were obtained from the different 
treatment groups (Figure 4, see Supplementary data), showing 
that the protocol was reproducible and that the baseline cell 
isolates were comparable. Detailed analysis revealed increased 
proliferation of MSCs from ZA-treated animals, especially in 
the intact group treated with ZA on a weekly basis, where the 
total number of PDs reached during 7 passages was higher (p 
= 0.007) and the average population doubling time (PDT) was 
Figure 1. Fracture healing. Representative images of fracture healing 
at 8-week endpoint presented as digital radiography (left panels), µCT 
section (center panels), and histological section (Weigert’s hematoxy-
lin, Alcian blue, and van Gieson) (right panels) of rats treated with pla-
cebo (upper row), bolus ZA (middle row), and ZA on a weekly basis 
(bottom row). 
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shorter (p = 0.009). A similar trend was seen in animals with 
fracture (Figure 3). The trend was similar for the maximum 
number of PDs reached during a single passage (P1–7), both 
in intact animals and in animals with fracture (Figure 4, see 
Supplementary data). 
MSCs from all groups were successfully induced into 
osteoblasts (Figure 5, see Supplementary data) but no statisti-
cally signifi cant differences between the bolus or weekly ZA-
treatment group and the placebo group were observed, either 
in intact animals or in animals with fracture (Figure 6, see 
Supplementary data). Interestingly, however, bolus ZA treat-
At the endpoint of the study (8 weeks), there were no detect-
able effects of ZA treatment on the levels of PINP and CTX 
markers. The results were the same whether analyses were 
performed on the separate treatment groups or whether the 
data from ZA-treated animals were pooled and compared 
against data from all placebo animals (data not shown). This 
justifi ed the pooling of treatment groups for statistical analysis 
of the fracture effect. When all the animals with fracture were 
pooled as 1 group and all the intact animals were pooled as 
1 group, there were no signifi cant differences in CTX levels 
between the animals with fracture (30 (SD 13) ng/mL) and 
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Figure 2. µCT-based quantifi cation of fracture callus and corresponding bone segment in intact animals. A and B. At the 8-week endpoint of the 
study, quantifi cation of the apparent callus formation in the fracture animals confi rmed statistically signifi cantly increased bone mineral content 
(BMC) (panel A) and bone volume (BV) (panel B) compared to the corresponding intact groups (Mann-Whitney U-test). Both bolus ZA treatment 
and weekly ZA treatment resulted in signifi cantly higher BMC and larger callus volume than in the placebo-treated fracture group (Mann-Whitney 
U-test). C. Neither ZA treatment nor fracture had any statistically signifi cant effect on BMD (Student’s t-test). Data are median, with box plot whis-
kers showing range (min to max). a p < 0.05, b p < 0.01.
Placebo ZA
bolus
ZA
weekly
Placebo ZA
bolus
ZA
weekly
––––– INTACT ––––– ––– FRACTURE –––
b b
Placebo ZA
bolus
ZA
weekly
Placebo ZA
bolus
ZA
weekly
––––– INTACT ––––– ––– FRACTURE –––
16
14
12
10
8
6
4
2
0
Total PDs (P1–7) Minimum PDT P1–7 (days)
6
5
4
3
2
1
0
Figure 3. Proliferative capacity of rat MSCs. The long-term proliferative capacity was assessed 
as the total cumulative number of population doublings (total PDs) reached throughout pas-
sage 7 (P1–7) (panel A), while the proliferation rate was assessed as days per PD, and 
presented as minimum PD time in days recorded at a single passage (P1–7) (panel B). In 
the intact groups, MSCs from the animals treated with ZA on a weekly basis had a higher 
long-term proliferative capacity (p = 0.007) (A), and higher proliferation rate (p = 0.009) (B) 
compared to the corresponding placebo groups. All pairwise comparisons performed with 
Student’s t-test. Point graphs with mean value indication, b p < 0.01
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ment resulted in the highest ALP activity 
and ALP-stained area, while weekly ZA 
treatment always gave the lowest levels, 
possibly indicating that bolus ZA treatment 
stimulated the osteogenic differentiation 
of MSCs—and/or that weekly ZA treat-
ment suppressed it. We therefore compared 
each parameter further in the bolus ZA and 
weekly ZA groups, and found that bolus 
treatment did indeed result in higher ALP 
activities than weekly treatment, both in 
intact animals (p = 0.04) and in animals 
with fracture (p = 0.02). The inter-individ-
ual variation was remarkably high in ALP- 
and von Kossa-stained areas (Figure 6, see 
Supplementary data), thus diminishing 
the statistical power of analysis for these 
parameters.
ZA had no effect on serum bone 
markers at the 8-week endpoint, 
but animals with fracture had higher 
serum PINP levels
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intact animals (30 (SD 10) ng/mL), while serum PINP levels 
were higher in animals with fracture than in intact animals 
(7.7 (SD 2.2) ng/mL vs. 6.6 (SD 1.3) ng/mL; p = 0.05).    
Ex vivo osteoblastic differentiation of MSCs corre-
lated with in vivo serum bone markers
There were correlations between serum PINP levels on the 
one hand and both cellular ALP activity (R = 0.44; p = 0.007) 
and ALP-stained areas (R = 0.32; p = 0.06) on the other, after 
2 weeks of osteoblastic differentiation culturing. In line with 
this fi nding, an inverse correlation was observed between 
CTX and ALP (R = −0.33; p = 0.05). However, no associa-
tions were found between in vitro mineralization (von Kossa-
stained area) and serum bone markers.  
Discussion 
This is the fi rst study on the effects of in vivo-administered 
ZA and fracture on ex vivo properties of MSCs. MSCs iso-
lated from bone marrow of ZA-treated rats were found to have 
increased proliferative capacity, but no substantial effects on 
osteoblastic differentiation were observed. 
Interestingly, pro-proliferative effects of in vivo treatment 
with ZA on a weekly basis were detected several weeks after 
harvest, indicating that there might be something intrinsically 
different in those MSCs that have been in contact with ZA 
in vivo. One explanation would be that these MSCs show an 
increased stimulatory response in vitro, since MSCs from an 
osteogenically suboptimal in vivo environment are known to 
show increased responsiveness when transferred to more opti-
mal in vitro conditions (Zhou et al. 2010). 
Previous in vitro studies have found both stimulatory and 
inhibitory effects of BPs on osteoblastic cells. The contradic-
tory results appear to depend on the source of cells and the 
type and concentration of bisphosphonate (Bellido and Plot-
kin 2011, Maruotti et al. 2012). BPs have been reported to 
increase bone tissue maturity (Gourion-Arsiquaud et al. 2010) 
and wall thickness in vivo, which refl ects focally elevated 
osteoblast numbers or activity (Balena et al. 1993, Storm et 
al. 1993, Boyce et al. 1995). Interestingly, humans treated for 
3 years with ZA showed an increased mineral apposition rate 
consistent with an increase in osteoblast activity (Recker et 
al. 2008), while others did not show such effects with other 
BPs (Chavassieux et al. 1997, Bravenboer et al. 1999). Our 
results indicate that in vivo ZA administration could be linked 
to stimulated MSC proliferation rather than increased osteo-
genesis, especially with weekly doses.
The degree of fracture healing at the 8-week endpoint 
is in line with the results of McDonald et al. (2008), who 
clearly demonstrated that ZA treatment did not delay endo-
chondral fracture repair but affected the callus remodeling, 
as well as giving increased callus strength compared to the 
placebo group. Weekly ZA dosing was associated with fur-
ther increases in callus BMC and BV at 6, 12, and 26 weeks 
and delayed remodeling compared to single ZA dosing. Our 
results agree with these fi ndings, even though we could only 
show a trend of increased callus BMC and BV in weekly 
dosing compared to single ZA dosing. There was a lower (but 
statistically insignifi cant difference in) BMD in the bolus ZA 
group with fracture than in the placebo group with fracture (p 
= 0.058). This was probably a refl ection of the large fracture 
callus in the ZA bolus group—as indicated by the increased 
bone volume and subsequently increased total BMC—but 
consisting of immature bone tissue with a lower degree of 
mineralization per square cm.
Due to practical limitations, the present study was per-
formed as 4 separate sub-series. Importantly, however, ani-
mals from each experimental group were randomly included 
in each series to strengthen the validity of the analysis. Con-
versely, the variation between individual animals and between 
different sub-series was a major limitation, making statisti-
cal analysis challenging and attenuating the statistical power. 
However, we chose to culture cells from each animal sepa-
rately instead of pooling cells from different animals. This 
approach is especially relevant when one is aiming to apply 
data from a preclinical animal model to the clinical setting, 
since it mimics the true individual variation. This approach 
also enabled analysis of correlation between bone turnover in 
vivo and MSC differentiation capacity ex vivo. 
To investigate bone turnover more mechanistically, we also 
evaluated the biochemical markers PINP and CTX in rela-
tion to fracture and/or ZA treatment. PINP levels at 8 weeks 
were higher in animals with fracture than in intact animals, 
indicating an active bone remodeling phase of fracture repair. 
However, no differences were observed in CTX levels. Sur-
prisingly, ZA treatment had no effect on serum bone mark-
ers, although reduced marker levels were expected due to 
suppressed bone remodeling (Szulc 2012). Interestingly, we 
nevertheless observed that there was a positive correlation 
between PINP and the in vitro osteoblastic differentiation 
capacity of MSCs, while a negative correlation was observed 
with CTX, suggesting that in vitro investigation of the osteo-
genic capacity of BM cells can refl ect the in vivo situation at 
the time of harvest. 
In conclusion, our results demonstrate that the pro-prolif-
erative effects of weekly ZA treatment in vivo can still be 
observed in isolated cells ex vivo several weeks after adminis-
tration of the drug. However, the fi nal conclusion as to whether 
this (a) is a direct effect of ZA on MSCs, (b) is an indirect 
effect mediated through ZA affecting other cells in the BM, or 
(c) refl ects a compensatory response of MSCs upon “release” 
from BP-induced suppression of bone turnover, remains open. 
Although it is diffi cult to estimate how well our results can be 
translated into possible effects of ZA on BM cells in patients, 
our study strongly supports future research focusing on effects 
of BPs on osteoblast lineage cells to gain a better understand-
ing of the mechanisms.
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Supplementary data
Figures 4–6 are available on the Acta Orthopaedica website, 
www.actaorthop.org, identifi cation number 9890.
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